Loading...
XSWX
BION
Market cap2.15bUSD
Aug 08, Last price  
31.50CHF
1D
-0.32%
1Q
8.62%
Jan 2017
-42.83%
IPO
76.17%
Name

BB Biotech AG

Chart & Performance

D1W1MN
No data to show
P/E
22.91
P/S
15.58
EPS
1.37
Div Yield, %
6.35%
Shrs. gr., 5y
-0.21%
Rev. gr., 5y
-30.44%
Revenues
112m
P
332,660,000318,065,000073,820,00054,293,0001,578,000-1,269,000376,820,000937,893,0001,476,387,000659,227,000-796,446,000693,053,000-465,753,000685,238,000699,233,000-396,220,000-351,227,000-199,567,000111,632,000
Net income
76m
P
317,993,000297,395,000-265,411,00045,353,00036,626,000-146,348,000-65,138,000367,834,000931,834,0001,470,139,000652,816,000-802,065,000687,503,000-471,343,000677,431,000691,174,000-404,808,000-357,812,000-206,607,00075,899,000
CFO
305m
+39.53%
-6,141,000-19,804,000201,017,000509,390,000167,838,000-23,411,000169,521,000367,834,000931,834,0001,470,139,000652,816,000-802,065,000687,503,000-471,343,000215,021,000262,449,000-94,787,000-357,812,000218,276,000304,560,000
Dividend
Mar 25, 20242 CHF/sh

Profile

BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.
URL
https://www.bbbiotech.ch/
IPO date
Nov 08, 2006
Employees
10
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
111,632
-155.94%
(199,567)
-43.18%
(351,227)
-11.36%
Cost of revenue
27,231
5,794
5,430
Unusual Expense (Income)
NOPBT
84,401
(205,361)
(356,657)
NOPBT Margin
75.61%
102.90%
101.55%
Operating Taxes
54
79
61
Tax Rate
0.06%
NOPAT
84,347
(205,440)
(356,718)
Net income
75,899
-136.74%
(206,607)
-42.26%
(357,812)
-11.61%
Dividends
(109,692)
(156,311)
(212,242)
Dividend yield
5.65%
6.67%
6.94%
Proceeds from repurchase of equity
(3,132)
(27,303)
BB yield
0.16%
0.89%
Debt
Debt current
117,500
363,000
Long-term debt
363,000
Deferred revenue
Other long-term liabilities
(363,000)
Net debt
(2,289,839)
(5,269,929)
(2,327,297)
Cash flow
Cash from operating activities
304,560
218,276
(357,812)
CAPEX
Cash from investing activities
588,943
Cash from financing activities
(305,202)
(220,213)
(233,271)
FCF
84,347
2,841,747
231,753
Balance
Cash
2,407,339
2,635,215
1,948
Long term investments
2,634,714
3,051,349
Excess cash
2,401,757
5,279,907
3,070,858
Stockholders' equity
2,325,932
2,359,725
2,722,643
Invested Capital
77,860
260,772
326,381
ROIC
49.82%
ROCE
3.51%
EV
Common stock shares outstanding
54,832
54,846
55,364
Price
35.40
-17.19%
42.75
-22.55%
55.20
-28.45%
Market cap
1,941,036
-17.21%
2,344,666
-23.28%
3,056,075
-28.45%
EV
(348,803)
(2,925,262)
728,778
EBITDA
84,401
(205,361)
(356,657)
EV/EBITDA
14.24
Interest
5,802
1,726
Interest/NOPBT